Radiolabeled antibodies in renal cell carcinoma

Cancer Imaging

Volumn 7, Issue 1, 2007, Pages 179-188

  Stillebroer, Alexander B ^a   Oosterwijk, Egbert ^a   Oyen, Wim J G ^a   Mulders, Peter F A ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody dependent cellular cytotoxicity; Immunoscintigraphy; Iodine; Lutetium; indium; Radioimmunotherapy; RIT

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; REVIEW; SCINTISCANNING;

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 38449086211     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.0025     Document Type: Article

References (92)

1. JemalA, SiegelR, WardE, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. DeKernionJB. Real numbers. In: Campbell's urology. Philadelphia: WB Saunders; 1986.
3. SkinnerDG, ColvinRB, VermillionCD, PfisterRC, LeadbetterWF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28: 1165-77.
4. Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996; 14: 216-22. (Pubitemid 26386712)
5. PantuckAJ, ZismanA, BelldegrunAS. The changingnatural history of renal cell carcinoma. J Urol 2001; 166: 1611-23.
6. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-66. (Pubitemid 35402959)
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17. (Pubitemid 30060482)
8. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20: 303-21. (Pubitemid 23154480)
9. EhrlichP. Collected studies on immunology. New York: John Wiley; 1906.
10. KohlerG, MilsteinC. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
11. Larson SM. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P. Pendergrass New Horizons Lecture. Radiology 1987; 165: 297-304. (Pubitemid 17156850)
12. LarsonSM, DivgiCR, ScottAM. Overview of clinical radioimmunodetection of human tumors. Cancer 1994; 73: 3 Suppl: 832-5.
13. MachJP, PelegrinA, BucheggerF. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol 1991; 3: 685-93.
14. Goldenberg DM. Current status of cancer imaging with radiolabeled antibodies. J Cancer Res Clin Oncol 1987; 113: 203-8. (Pubitemid 17120592)
15. GoldenbergDM, LarsonSM, ReisfeldRA, SchlomJ. Targeting cancer with radiolabeled antibodies. Immunol Today 1995; 16: 261-4.
16. Oosterwijk E, Divgi CR, Brouwers A, et al. Monoclonal antibodybased therapy for renal cell carcinoma. Urol Clin North Am 2003; 30: 623-31. (Pubitemid 37059567)
17. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001; 74: 7-25. (Pubitemid 32727605)
18. EisenNH, KestonAS. The immunologic reactivity of bovine serum albumin labeled with trace-amounts of radioactive iodine (1-131). J Immunol 1950; 63: 71-80.
19. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005; 24: 539-67. (Pubitemid 43097000)
20. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European Delphi process. Eur J Radiol 2001; 37: 8-17. (Pubitemid 32215440)
21. ReubiJC, KvolsL. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992; 52: 6074-8.
22. 111In-DPTA- D-Phel]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma. Cancer Biother Radiopharm 1999; 14: 59-64.
23. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427. (Pubitemid 37056239)
24. WalshJ. Gastrin. In: Walsh JH, Dockray GJ, editors. Gut peptides: biochemistry and physiology. New York: Raven Press, 1994: 75-121.
25. WankSA, PisegnaJR, de WA. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A 1992; 89: 8691-5.
26. Gotthardt M, Bene MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006; 33: 1273-9. (Pubitemid 44630781)
27. OttawayCA. Insertion and internalization of vasoactive intestinal peptide (VIP) receptors in murine CD4T lymphocytes. Regul Pept 1992; 41: 49-59.
28. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60: 3105-12. (Pubitemid 30395841)
29. Pedrazzini T, Seydoux J, Kunstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998; 4: 722-6. (Pubitemid 28274675)
30. Korner M, Waser B, Reubi JC. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int J Cancer 2005; 115: 734-41. (Pubitemid 40776696)
31. Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 1987; 47: 821-5. (Pubitemid 17027980)
32. Pansky A, de Weerth A, Fasler-Kan E, et al. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J Am Soc Nephrol 2000; 11: 1409-18. (Pubitemid 30483457)
33. Waser B, Eltschinger V, Linder K, Nunn A, Reubi JC. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer (177)Lu-AMBA. Eur J Nucl Med Mol Imaging 2007; 34: 95-100. (Pubitemid 44885559)
34. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-43. (Pubitemid 47604973)
35. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000; 275: 21785-8. (Pubitemid 30621742)
36. BrooksPC. Role of integrins in angiogenesis. Eur J Cancer 1996; 32A: 2423-9.
37. Wechsel HW, Petri E, Feil G, Nelde HJ, Bichler KH, Loesr W. Renal cell carcinoma: immunohistological investigation of expression of the integrin alpha v beta 3. Anticancer Res 1999; 19(2C): 1529-32. (Pubitemid 29255640)
38. Bander NH, Cordon-Cardo C, Finstad CL, et al. Immunohistologic dissection of the human kidney using monoclonal antibodies. J Urol 1985; 133: 502-5. (Pubitemid 15129826)
39. Bander NH, Finstad CL, Cordon-Cardo C, et al. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 1989; 49: 6774-80. (Pubitemid 20008821)
40. Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF, Melamed MR, Old LJ. Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci U S A 1985; 82: 2955-9. (Pubitemid 15097771)
41. FischerP, StorkelS, HaaseW, ScherberichJE. Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyl-transferase. Cancer Immunol Immunother 1991; 33: 382-8.
42. Kinouchi T, Nakayama E, Ueda R, et al. Characterization of a kidney antigen defined by a mouse monoclonal antibody K2.7. J Urol 1987; 137: 151-4. (Pubitemid 17214253)
43. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-94. (Pubitemid 16006918)
44. Oosterwijk E, Ruiter DJ, Wakka JC, et al. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol 1986; 123: 301-9. (Pubitemid 16072530)
45. TokuyamaH, TokuyamaY. Mouse monoclonal antibodies with restricted specificity for human renal cell carcinoma and ability to modulate the tumor cell growth in vitro. Hybridoma 1988; 7: 155-65.
46. VessellaRL, LangePH, PalmeDF, ChiouRK, ElsonMK, WesselsBW. Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice. Targeted Diagn Ther 1988; 1: 245-82.
47. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of for-malin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res 1989; 49: 1802-9. (Pubitemid 19108408)
48. Chiou RK, Vessella RL, Elson MK, et al. Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Res 1985; 45(12 Pt 1): 6140-6. (Pubitemid 16224772)
49. VessellaRL, ChiouRK, GrundFM. Renal cell carcinoma (RCC) phase I-II trials with 131-1 labeled monoclonal antibody A6H: imaging and pharmacokinetic studies. Proc Am Assoc Cancer Res 1987; 28-480 (Abstract 1525).
50. Vessella RL, Moon TD, Chiou RK, et al. Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. Cancer Res 1985; 45(12 Pt 1): 6131-9. (Pubitemid 16224771)
51. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398-408. (Pubitemid 27078826)
52. BrouwersAH, BuijsWC, OosterwijkE, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 2003; 9( 10 Pt 2): S3953-60.
53. Bismar TA, Bianco FJ, Zhang H, et al. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology 2003; 35: 513-7. (Pubitemid 38041287)
54. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 2005; 11: 6558-66. (Pubitemid 41338995)
55. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-6. (Pubitemid 29458875)
56. Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 2004; 287: F1-6. (Pubitemid 38780576)
57. KranenborgMH, BoermanOC, de WeijertMC, OosterwijkWakka JC, Corstens FH, Oosterwijk E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997; 80: 12 Suppl): 2390-7.
58. 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998; 13: 133-9.
59. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999; 19(2A): 1197-200. (Pubitemid 29257558)
60. van DijkJ, OosterwijkE, van KroonenburghMJ, et al. Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med 1988; 29: 1078-82.
61. van Dijk J, Uemura H, Beniers AJ, Peelen WP, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994; 56: 262-8. (Pubitemid 24076129)
62. van DijkJ, ZegveldST, FleurenGJ, WarnaarSO. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991; 48: 738-43.
63. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-50. (Pubitemid 23105683)
64. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-39. (Pubitemid 28523499)
65. OosterwijkE, DebruyneFM, SchalkenJA. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 1995; 22: 34-41.
66. Surfus JE, Hank JA, Oosterwijk E, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996; 19: 184-91. (Pubitemid 26234612)
67. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sei U S A 1984; 81: 6851-5. (Pubitemid 15221019)
68. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiât Oncol 2003; 13: 176-81. (Pubitemid 36962641)
69. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 985-90. (Pubitemid 38495816)
70. FyfeG, FisherRI, RosenbergSA, SznolM, ParkinsonDR, LouieAC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-96.
71. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-21. (Pubitemid 40685588)
72. Brouwers AH, Boerman OC, Oyen WJ. In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer. Clin Cancer Res 2005; 11(24Pt 1): 8886. (Pubitemid 43005942)
73. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51: 171-7. (Pubitemid 34298113)
74. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 57-62. (Pubitemid 41797084)
75. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 1529-37. (Pubitemid 27167389)
76. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5: 10 Suppl): s3268-74.
77. 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 1412-21.
78. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713. (Pubitemid 34507123)
79. 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 6540-8.
80. Carrasquillo JA, Mulshine JL, Bunn PA Jr, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 1987; 28: 281-7. (Pubitemid 17049459)
81. Yokoyama K, Carrasquillo JA, Chang AE, et al. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 1989; 30: 320-7. (Pubitemid 19077321)
82. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994; 35: 899-908. (Pubitemid 24151232)
83. GeisslerF, AndersonSK, VenkatesanP, PressO. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992; 52: 2907-15.
84. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56: 2123-9. (Pubitemid 26119913)
85. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 44: 179-88. (Pubitemid 27278391)
86. 186Re. J Nucl Med 2004; 45: 327-37.
87. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44: 400-11. (Pubitemid 39586017)
88. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24: 823-34. (Pubitemid 46671186)
89. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, et al. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med 2005; 46: 495-501. (Pubitemid 43093160)
90. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, de Weijert MC, Corstens FH, Oosterwijk E. Two-step radioimmunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies. Int J Cancer 1998; 75: 74-80. (Pubitemid 28113980)
91. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270-8. (Pubitemid 28481621)
92. PressOW, EaryJF, AppelbaumFR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-40.